Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer

Lenz, HJ; Philip, P; Saunders, M; Kolevska, T; Mukherjee, K; Samuel, L; Bondarde, S; Dobbs, T; Tagliaferri, M; Hoch, U; Hannah, AL; Berkowitz, M

Lenz, HJ (reprint author), USC Norris Comprehens Canc Ctr, 1441 Eastlake Ave Rm 3456, Los Angeles, CA 90089 USA.

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017; 80 (6): 1161

Abstract

Etirinotecan pegol (EP) is a long-acting topoisomerase-I inhibitor designed to provide sustained exposure to SN-38 (active metabolite of irinotecan). ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索